Wipff et al. reported efficacy rates of 41% for sulfasalazine, 37.5% for methotrexate, 75% for bisphosphonates, and 89% for anti-TNF-α agents in treating CRMO. Here, TNF is linked to chronic recurrent multifocal osteomyelitis.